This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Actavis, Mylan appeal certification orders in US pharma antitrust litigation

( October 15, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Actavis and Mylan asked the US Court of Appeals for the Third Circuit to reverse the grant of class certification for direct purchasers and end-payers of generical pharmaceuticals. They said that in certifying the direct purchasers, the lower court treated two core requirements—numerosity and predominance—as speedbumps. As to end-payers, they argued that class certification is impossible to ascertain because they failed to account for the extensive variations among multi-step payment chains and the individualized contracts governing EPPs’ thousands of payments. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login